PXL 01

Drug Profile

PXL 01

Alternative Names: PXL-01

Latest Information Update: 30 Sep 2016

Price : $50

At a glance

  • Originator PharmaSurgics
  • Class Glycoproteins; Peptides
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Post-surgical adhesions

Most Recent Events

  • 30 Sep 2016 Promore Pharma plans a phase III trial for Post-surgical adhesions (Prevention) in Europe (Promore Pharma pipeline, September 2016)
  • 05 Jul 2016 Pergamum is now called ProMore Pharma
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top